Oxford targets life science companies engaged in a variety of scientific pursuits. Our clients' specialties include pharmaceuticals, enabling technologies and tools, genomics and proteomics, medical devices and agricultural biotechnology. We lend to companies at various stages of development, including those that have secured early- and expansion-round funding, as well as to mezzanine-stage and public companies. In general, our clients have:   Top-tier investors     Capital in reserve     Indications of a high probability of significant future equity investment from existing investors     Strong, experienced core management and technical teams     Unique product concepts or a business model indicating high growth potential     A focus on markets with unmet needs and limited competition     Collateral with strong market value